US5310929A - Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists - Google Patents
Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists Download PDFInfo
- Publication number
- US5310929A US5310929A US07/926,795 US92679592A US5310929A US 5310929 A US5310929 A US 5310929A US 92679592 A US92679592 A US 92679592A US 5310929 A US5310929 A US 5310929A
- Authority
- US
- United States
- Prior art keywords
- alkyl
- alkoxy
- methyl
- ethyl
- imidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- This invention relates to substituted imidazoles useful as angiotensin II (AII) blockers, and more particularly, to prodrugs of imidazole carboxylic acids which are AII antagonists useful in treating hypertension or congestive heart failure.
- AII angiotensin II
- European Patent Application Publication Number 0 434 249 A2 published Jun. 26, 1991 describes benzofuran derivatives useful in treatment or prophylaxis of hypertension and potentially useful for the treatment of cognitive disorders and other diseases such as renal failure, hyperaldosteronism, cardiac insufficiency, congestive heart failure, post-myocardial infarction, cerebrovascular disorders, glaucoma and disorders of intracellular homeostasis.
- R 7 is H or C1-C4-alkyl
- R 11 is H, C1-C5-alkyl or benzyl
- R 14 is CF 3 , C1-C5-alkyl, or phenyl
- R 16 is H or CH 2 O 2 CC(CH 3 ) 3 ;
- this invention relates to pharmaceutical compositions comprising a pharmaceutically suitable carrier and a therapeutically effective amount of the compounds of this invention.
- this invention concerns a method of treating congestive heart failure in a warm-blooded animal comprising orally administering to the animal a therapeutically effective amount of a compound of the invention.
- the compounds of this invention exhibit remarkable and unexpected potency as antihypertensive agents in comparison to the compounds specifically disclosed in EPA 0 253 310 and WO 89/06233 which have been tested.
- R 3 is C1-C5-alkyl, C2-C5-alkenyl, C2-C5-alkynyl;
- R 11 is H, C1-C5-alkyl or benzyl
- R 12 and R 13 are independently H, C1-C5-alkyl, phenyl or benzyl;
- R 14 is CF 3 , C1-C5-alkyl, or phenyl
- R 16 is H or CH 2 O 2 CC(CH 3 ) 3 ;
- p 1-5;
- r 0-2;
- s and s' are 0-5;
- p 1;
- R 1 is ##STR11##
- R 2 is H;
- R 3 is C1-C5-alkyl;
- R 5 is --(CH 2 ) s CH(R 7 )(CH 2 ) s ,O 2 CR 8 ;
- R 7 is H
- p 1;
- This invention also relates to pharmaceutical compositions containing these novel imidazole carboxylic acids and pharmaceutical methods using them.
- Pharmaceutically acceptable salts include both the metallic (inorganic) salts and organic salts; a list of which is given in Remington's Pharmaceutical Science, 7th Edition, page 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowability, hydroscopicity and solubility. Preferred salts of this invention for the reasons cited above include potassium, sodium, calcium and ammonium salts.
- compositions comprising a suitable pharmaceutical carrier and a compound of Formula I to treat hypertension or congestive heart failure.
- the compounds of Formula I can be prepared using the reagents and materials described herein. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected.
- Biphenyl compounds (10) or (12) can be prepared using the procedure illustrated in Scheme 2 below. Boronic acids (6) or (7) are coupled to halides (8) using tetrakis(triphenylphosphine) palladium catalyst in toluene and 2M sodium carbonate to produce biphenyl compounds (9(a,b)) as described in Syn. Comm., 11: 513 (1981). Bromination of biphenyl compounds (9a) with N-bromosuccinimide (NBS) using azobisisobutyrylnitrile (AIBN) as a catalytic initiator according to the procedure described in U.S. Pat. No. 4,820,843 issued Apr. 11, 1989 produces the corresponding bromide compounds (10).
- NBS N-bromosuccinimide
- AIBN azobisisobutyrylnitrile
- compound (9b) can be hydrolyzed with aqueous mineral acid then reprotected with isobutylene and a catalytic amount of sulfuric acid to produce t-butyl esters (11) which can be brominated using NBS to produce the corresponding bromides (12).
- t-butyl esters (11) which can be brominated using NBS to produce the corresponding bromides (12).
- the wet cake was re-slurried in 8 L acetone and 8 L of water was added slowly. The suspension was stirred for 1 hour then filtered. The filter cake was rinsed with 3 to 5 L of water. The white solid was dried in a vacuum oven at 40°-45° C. to a constant weight of 3.0 kg, mp 158°-160° C.
- Part D Preparation of 2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl-4-yl)methane
- Part G Preparation of 4-Ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylic acid
- Part H Preparation of 4-Ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4-yl]methyl]imidazole-5-carboxylic acid
- Part B Preparation of Acetoxymethyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
- Part B Preparation of Isobutyryloxymethyl 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl)biphenol-4-yl]methyl]imidazole-5-carboxylate
- Part B Preparation of Methoxycarbonyloxymethyl 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4-yl[methyl[imidazole-5-carboxylate
- the title compound can be obtained using the procedure described in Example 4 above using chloromethyl methoxydimethylacetate.
- Part B Preparation of t-Butoxycarbonyloxymethyl 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4-yl]methyl]imidazole-5-carboxylate
- Part B Preparation of 1-Acetoxyethyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
- Part B Preparation of 1-(t-Butoxycarbonyl)ethyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
- Part B (1,3-Dioxa-5-methyl-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
- cuprous chloride 0.24 g was suspended in 100 mL diethyl ether and then 22.1 g of propionyl chloride was added. The reaction was heated to reflux and 88 mL of t-butyl magnesium chloride was added slowly to maintain reflux. The reaction was stirred overnight then poured into 200 g ice and the pH adjusted to 8 with solid NaHCO 3 . The reaction was extracted with ether, washed with 10% aq. NaHCO 3 , water and then brine followed by MgSO 4 drying. The product was purified by distillation to give 12.5 g of the ketone.
- Part B 4-Bromomethyl-5-(1.1-dimethylethyl)-1.3-dioxacyclopenten-2-one
- This material was prepared from 2,2-dimethyl-4-hydroxy-3-pentanone by the literature procedure described in (Chem. Pharm. Bull. 32, 2241 (1984)).
- Part C Preparation of (5-(1,1-Dimethylethyl)-1,3-dioxa-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-[[2'-(N-triphenyl methyl(tetrazol-5-yl))biphenol-4-yl[methyl[imidazole-5-carboxylate
- 0.620 g of the title compound was obtained from 0.32 g 4-bromomethyl-5-(1,1-dimethylethyl)-1,3-dioxacyclopenten-2-one and 0.60 g 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4yl]methyl]imidazole-5-carboxylic acid using the method shown in Example 13 above.
- Part D Preparation of (5-(1.1-Dimethylethyl)-1.3-dioxa-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylate
- 0.40 g of the title compound was obtained from 0.62 g (5-(1,1-dimethylethyl)-1,3-dioxa-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))bihenyl-4-yl]methyl]imidazole-5-carboxylate using the method shown in Example 13 above.
- Part B 1.3-Dioxa-4-methyl-5-phenyl-cyclopenten-2-one
- This compound was prepared from 2-hydroxypropiophenone by the literature procedure described in Liebigs Ann. Chem. 764, 116 (1972).
- This compound was prepared from 1,3-dioxa-4-methyl-5-phenyl-cyclopenten-2-one by the literature procedure described in Chem. Pharm. Bull. 32, 2241 (1984).
- Part D (1.3-Dioxa-5-phenyl-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4-yl]methyl]imidazole-5-carboxylate
- 0.220 g of the title compound were obtained from 0.3826 g 4-bromomethyl-1,3-dioxa-5-phenyl-cyclopenten-2-one and 0.6588 g 4-ethyl-2-propyl-1-[[2'-(N-triphenylmethyl(tetrazol-5-yl))biphenyl-4yl]methyl]imidazole-5-carboxylic acid using the procedure described in Example 1 above.
- Part E Preparation of (1,3-Dioxa-5-phenyl-cyclopenten-2-one-4-yl)methyl 4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl[methyl]imidazole-5-carboxylate
- Angiotensin-II produces numerous biological responses (e.g. vasoconstriction) through stimulation of its receptors on cell membranes.
- AII antagonists which are capable of interacting with the AII receptor
- a ligand-receptor binding assay was utilized for the initial screen. The assay was carried out according to the method described by [Chiu, et al., Receptor, 1 33, (1990)]. In brief, aliquots of a freshly prepared particulate fraction of rat adrenal cortex were incubated with 0.05 nM [ 125 I]AII and varying concentrations of potential AII antagonists in a Tris buffer.
- the compounds of this invention are found to exhibit an activity of at least IC 50 ⁇ 10 micromolar, thereby demonstrating and confirming the activity of these compounds as effective AII antagonists. Results are presented in Table 3.
- the potential antihypertensive effects of the compounds of this invention may be demonstrated by administering the compounds to awake rats made hypertensive by ligation of the left renal artery [Cangiano, et al., J. Pharmacol. Exp. Ther., 1979, 208, 310]. This procedure increases blood pressure by increasing renin production with consequent elevation of AII levels.
- Compounds are administered intravenously via cannula in the jugular vein to give a cumulative dose of 10 mg/kg.
- Arterial blood pressure is continuously measured directly through a carotid artery cannula and recorded using a pressure transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels to determine the antihypertensive effects of the compounds.
- the compounds of this invention are found to exhibit an activity (intravenous) which is 10 mg/kg or less, and/or an activity (oral) which is 100 mg/kg or less, thereby demonstrating and confirming the utility of these compounds as effective agents in lowering blood pressure.
- an activity intravenous
- an activity oral
- results are described in Table 4.
- the compounds of the invention can be administered for the treatment of hypertension by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal.
- administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intraperitoneal.
- administration is by the oral route.
- the compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
- the compounds of the invention are useful in treating hypertension. They are also of value in the management of acute and chronic congestive heart failure and angina.
- renal diseases such as diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end stage renal disease, used in renal transplant therapy, and to treat renovascular hypertension, scleroderma, left ventricular dysfunction, systolic and diastolic dysfunction, diabetic retinopathy and in the management of vascular disorders such as migrane, Raynaud's disease, and as prophylaxis to minimize the atherosclerotic process and neointimal hyperplasia following angioplasty or vascular injury and to retard the onset of type II diabetes.
- renal diseases such as diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end stage renal disease, used in renal transplant therapy, and to treat renovascular hypertension, scleroderma, left ventricular dysfunction, sy
- the compounds of this invention may also be used in combination with other medications for the treatment of glaucoma including choline esterase inhibitors such as physostigmine salicylate or demecarium bromide, parasympathomimetic agents such as pilocarpine nitrate, ⁇ -adrenergic antagonists such as timolol maleate, adrenergic agonists such as epinephrine and carbonic anhydrase inhibitors such as MK-507.
- choline esterase inhibitors such as physostigmine salicylate or demecarium bromide
- parasympathomimetic agents such as pilocarpine nitrate
- ⁇ -adrenergic antagonists such as timolol maleate
- adrenergic agonists such as epinephrine
- carbonic anhydrase inhibitors such as MK-507.
- a warm-blooded animal as used herein means a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
- the compounds of this invention may be utilized with a pharmaceutical carrier in compositions such as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.
- the compounds of this invention can be administered a warm-blood animal in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
- the dosage range will generally be about 1 to 1000 mg per patient per day which can be administered in single or multiple doses.
- the dosage range will be about 5 to 500 mg per patient per day; more preferably about 5 to 300 mg per patient per day.
- the compounds of this invention can also be administered in combination with other antihypertensives and/or diuretics.
- the compounds of this invention can be given in combination with diuretics such as hydrochlorothiazide, chlorothiazide, chlorthalidone, methylclothiazide, furosemide, ethacrynic acid, triamterene, amiloride spironolactone and atriopeptin; calcium channel blockers, such as diltiazem, felodipine, nifedipine, amlodipine, nimodipine, isradipine, nitrendipine and verapamil; ⁇ -adrenergic antagonists such as timolol, atenolol, metoprolol, propanolol, nadolol and pindolol; angiotensin converting enzyme inhibitors such as enalapril, lisinopril, captopri
- the individual daily dosages for these combinations can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly.
- one of the angiotensin-II antagonists of this invention effective clinically in the 5-500 milligrams per day range can be effectively combined at levels at the 1.0-500 milligrams per day range with the following compounds at the indicated per day dose range; hydrochlorothiazide (6-100 mg), chlorothiazide (1250-500 mg), furosemide (5-80 mg), propranolol (10-480 mg), timolol maleate (1-20 mg) methyldopa (125-2000 mg), felodipine (1-20 mg), nifedipine (5-120 mg), nitrendipine (5-60 mg), and diltiazem (30-540 mg).
- triple drug combinations of hydrochlorothiazide (5-100 mg) plus amiloride (5-20mg) plus angiotensin-II antagonists of this invention (1-500 mg) or hydrochlorothiazide (5-100 mg) plus timolol maleate (5-60 mg) plus an angiotensin-II antagonists of this invention (1-500 mg) or hydrochlorothiazide (5-200 m g) and nifedipine (5-60 mg) plus an angiotensin-II antagonists of this invention (1-500 mg) are effective combinations to control blood pressure in hypertensive patients.
- these dose ranges can be adjusted on a unit basis as necessary to permit divided daily dosage and, as noted above, the dose will vary depending on the nature and severity of the disease, weight of patient, special diets and other factors.
- the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspension. It can also be administered parenterally, in sterile liquid dosage forms.
- Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated for film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated for film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
- parenteral solutions In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
- Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffer substances.
- Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
- citric acid and its salts and sodium EDTA are also used.
- parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
- Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol., a standard reference text in this field.
- Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:
- a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
- a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient.
- the capsules are washed and dried.
- a large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
- Appropriate coatings may be applied to increase palatability or delay absorption.
- a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
Abstract
Description
TABLE 1 ______________________________________ ##STR21## Ex- physical ample R.sup.1 R.sup.2 data ______________________________________ 1 propyl H NMR 2 CH.sub.2 N(CH.sub.3).sub.2 H NMR 3 CH.sub.2 O.sub.2 CCH.sub.3 H NMR 4 CH.sub.2 O.sub.2 CCH(CH.sub.3).sub.2 H NMR 5 CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 H NMR 6 CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 NMR 7 CH.sub.2 O.sub.2 COCH.sub.3 H NMR 8 CH.sub.2 O.sub.2 COC(OCH.sub.3)(CH.sub.3).sub.2 H NMR 9 CH.sub.2 O.sub.2 COC(CH.sub.3).sub.3 H NMR 10 CH(CH.sub.3)O.sub.2 CCH.sub.3 H NMR 11 CH(CH.sub.3)O.sub.2 COCH.sub.3 H NMR 12 CH(CH.sub.3) O.sub.2 COC(CH.sub.3).sub.3 H NMR 13 ##STR22## H NMR 14 ##STR23## H NMR 15 ##STR24## H TLC ______________________________________
TABLE 2 ______________________________________ ##STR25## Ex- am- ple R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 R.sup.6 ______________________________________ 16 Tet H Et Et CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 H 17 Tet H n-Pr Et CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 H 18 Tet H n-Bu Et CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 H 19 Tet H n-Pr Et CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 F 20 Tet H n-Pr C.sub.2 F.sub.5 CH.sub.2 O.sub.2 CC(CH.sub.3).sub.3 F 21 Tet Et n-Pr Cl CH.sub.2 O.sub.2 COC(CH.sub.3).sub.3 H 22 Tet n-Pr n-Bu Cl CH.sub.2 O.sub.2 COC(CH.sub.3).sub.3 H 23 Tet OEt n-Pr Cl CH.sub.2 O.sub.2 COC(OCH.sub.3)(CH.sub.3).sub .2 H 24 Tet H n-Bu n-Pr CH.sub.2 O.sub.2 COCH(CH.sub.3).sub.2 Me 25 Tet H n-Bu n-Pr CH.sub.2 O.sub.2 COCH(CH.sub.3).sub.2 Me ______________________________________ Tet = Tetrazole
TABLE 3 ______________________________________ Angiotensin II Example Receptor Binding IC.sub.50 nM ______________________________________ 2 100 5 2 6 20 7 3 9 6 10 20 11 4 12 5 13 3 14 3 15 6 ______________________________________
TABLE 4 ______________________________________ Oral Antihypertensive Effects in Renal Hypertensive Rats Examples ED.sub.30 mg/kg ______________________________________ 5 0.03 8 0.03 9 0.02 11 0.02 12 0.3 13 0.1 14 0.3 15 0.3 ______________________________________
Claims (10)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/926,795 US5310929A (en) | 1992-08-06 | 1992-08-06 | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
BR9306911A BR9306911A (en) | 1992-08-06 | 1993-08-02 | 5-imidazole carboxylic esters pharmaceutical compositions method of treating hypertension in a warm-blooded animal and method of treating congestive heart collapse in a warm-blooded animal and method of treating congestive heart collapse in a warm-blooded animal |
PL93307309A PL307309A1 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazocarboxylic acids as antagonists of angiotensin ii receptors |
EP93918463A EP0654027A1 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
PCT/US1993/007103 WO1994003435A1 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
CA002141692A CA2141692C (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
AU47903/93A AU688735B2 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
SG1996008109A SG47108A1 (en) | 1992-08-06 | 1993-08-02 | Produgs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
IL106553A IL106553A0 (en) | 1992-08-06 | 1993-08-02 | Substituted imidazoles and pharmaceutical compositions containing them |
HU9500349A HU9500349D0 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
SK131-95A SK13195A3 (en) | 1992-08-06 | 1993-08-02 | Imidazole carboxylic acids and pharmaceutical agent containing thereof |
JP6505415A JP2892838B2 (en) | 1992-08-06 | 1993-08-02 | Prodrugs of imidazolecarboxylic acid as angiotensin II receptor antagonists |
ZA935693A ZA935693B (en) | 1992-08-06 | 1993-08-05 | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
CN93117634A CN1090275A (en) | 1992-08-06 | 1993-08-06 | The prodrug of imidazole carboxylic acids as angiotensin II receptor antagonists |
MX9304787A MX9304787A (en) | 1992-08-06 | 1993-08-06 | PRODROGES OF IMIDAZOLCARBOXILIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
TW082106302A TW239131B (en) | 1992-08-06 | 1993-08-06 | |
FI950485A FI950485A (en) | 1992-08-06 | 1995-02-03 | Prodrug forms of imidazolecarboxylic acids as angiotensin II receptor antagonists |
NO950404A NO950404D0 (en) | 1992-08-06 | 1995-02-03 | Promoters of imidazole carboxylic acids as angiotensin II receptor antagonists |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/926,795 US5310929A (en) | 1992-08-06 | 1992-08-06 | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US5310929A true US5310929A (en) | 1994-05-10 |
Family
ID=25453732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/926,795 Expired - Lifetime US5310929A (en) | 1992-08-06 | 1992-08-06 | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
Country Status (18)
Country | Link |
---|---|
US (1) | US5310929A (en) |
EP (1) | EP0654027A1 (en) |
JP (1) | JP2892838B2 (en) |
CN (1) | CN1090275A (en) |
AU (1) | AU688735B2 (en) |
BR (1) | BR9306911A (en) |
CA (1) | CA2141692C (en) |
FI (1) | FI950485A (en) |
HU (1) | HU9500349D0 (en) |
IL (1) | IL106553A0 (en) |
MX (1) | MX9304787A (en) |
NO (1) | NO950404D0 (en) |
PL (1) | PL307309A1 (en) |
SG (1) | SG47108A1 (en) |
SK (1) | SK13195A3 (en) |
TW (1) | TW239131B (en) |
WO (1) | WO1994003435A1 (en) |
ZA (1) | ZA935693B (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459148A (en) * | 1992-12-17 | 1995-10-17 | Sankyo Company, Limited | Biphenyl derivatives and their use for the treatment of hypertension and cardiac disease |
US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
US5925664A (en) * | 1994-03-16 | 1999-07-20 | Sankyo Company, Limited | Method for treating ocular hypertension and glaucoma |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6271375B1 (en) | 1997-06-30 | 2001-08-07 | Zambon Group S.P.A. | Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes |
US6369236B1 (en) * | 1998-07-18 | 2002-04-09 | Aventis Pharma Deutschland Gmbh | Imidazole derivatives with biphenylsulfonyl substitution method for preparing them and their use as a drug or diagnostic agent |
US6372917B1 (en) * | 1998-07-18 | 2002-04-16 | Aventis Pharma Deutschland Gmbh | Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them |
US6573288B1 (en) * | 1998-05-06 | 2003-06-03 | Aventis Pharma Deutschland Gmbh | Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
WO2004065383A2 (en) * | 2003-01-16 | 2004-08-05 | Teva Pharmaceutical Industries Ltd. | Novel synthesis of irbesartan |
US20050187269A1 (en) * | 2004-02-25 | 2005-08-25 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
US20060074117A1 (en) * | 2004-09-02 | 2006-04-06 | Lilach Hedvati | Purification of olmesartan medoxomil |
WO2006115834A1 (en) * | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2129850T3 (en) * | 1994-09-20 | 1999-06-16 | Wakunaga Seiyaku Kk | PRODUCTION PROCEDURE OF A DERIVATIVE OF N-BIPHENYL METHYLTIADIAZOLINE OR A SALT OF IT AND ITS INTERMEDIATE PRODUCTION OF PRODUCTION. |
IT1295405B1 (en) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | USE OF AN ANGIOTENSIN II RECEPTORAL ANTAGONIST FOR DRUG PREPARATION TO INCREASE THE SURVIVAL RATE OF |
ES2154191B1 (en) * | 1998-11-24 | 2001-10-16 | Ferrer Int | NEW ACETALS DERIVED FROM THE 2-RENT-5-HALO-3- (2 '- (TETRAZOL-5-IL) -BIFENIL-4-ILMETIL) -3H-IMIDAZOL-4-CARBALDEHIDS. |
GR20000100281A (en) * | 2000-08-17 | 2002-05-24 | Ιωαννης Ματσουκας | Synthetic methods in the tre |
MXPA03011693A (en) | 2001-05-31 | 2004-12-06 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists. |
WO2005068632A1 (en) | 2004-01-20 | 2005-07-28 | Aichi Prefecture | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
ES2302671T1 (en) * | 2006-08-29 | 2008-08-01 | Teva Pharmaceutical Industries Ltd. | PROCEDURES FOR THE SYNTHESIS OF 5-PHENYL-1-TRITIL-1H-TETRAZOL. |
CA2663981C (en) * | 2006-10-09 | 2014-05-27 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
JP5290190B2 (en) * | 2006-12-06 | 2013-09-18 | サルブリス・アセット・マネイジメント・カンパニー・リミテッド | Salt of imidazole-5-carboxylic acid derivative, production method and pharmaceutical composition thereof |
EP2521545B1 (en) * | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
CN104610232B (en) * | 2013-11-01 | 2019-09-20 | 深圳信立泰药业股份有限公司 | A Lishatan ester is amorphous and preparation method thereof and contains the unbodied pharmaceutical composition |
EP4007592A1 (en) | 2019-08-02 | 2022-06-08 | LanthioPep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006233A1 (en) * | 1988-01-07 | 1989-07-13 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
WO1991000277A1 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Substituted imidazoles |
WO1991000281A2 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Fused-ring aryl substituted imidazoles |
EP0434249A2 (en) * | 1989-12-01 | 1991-06-26 | Glaxo Group Limited | Benzofuran derivatives |
EP0459136A1 (en) * | 1990-04-27 | 1991-12-04 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
WO1992000977A2 (en) * | 1990-07-13 | 1992-01-23 | E.I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69329982T2 (en) * | 1992-06-02 | 2001-09-27 | Sankyo Co | 4-carboxyimidazole derivatives as angiotensin II antagonists and their therapeutic use |
-
1992
- 1992-08-06 US US07/926,795 patent/US5310929A/en not_active Expired - Lifetime
-
1993
- 1993-08-02 EP EP93918463A patent/EP0654027A1/en not_active Withdrawn
- 1993-08-02 BR BR9306911A patent/BR9306911A/en not_active Application Discontinuation
- 1993-08-02 SG SG1996008109A patent/SG47108A1/en unknown
- 1993-08-02 PL PL93307309A patent/PL307309A1/en unknown
- 1993-08-02 AU AU47903/93A patent/AU688735B2/en not_active Ceased
- 1993-08-02 CA CA002141692A patent/CA2141692C/en not_active Expired - Lifetime
- 1993-08-02 WO PCT/US1993/007103 patent/WO1994003435A1/en not_active Application Discontinuation
- 1993-08-02 JP JP6505415A patent/JP2892838B2/en not_active Expired - Lifetime
- 1993-08-02 IL IL106553A patent/IL106553A0/en unknown
- 1993-08-02 HU HU9500349A patent/HU9500349D0/en unknown
- 1993-08-02 SK SK131-95A patent/SK13195A3/en unknown
- 1993-08-05 ZA ZA935693A patent/ZA935693B/en unknown
- 1993-08-06 CN CN93117634A patent/CN1090275A/en active Pending
- 1993-08-06 TW TW082106302A patent/TW239131B/zh active
- 1993-08-06 MX MX9304787A patent/MX9304787A/en unknown
-
1995
- 1995-02-03 NO NO950404A patent/NO950404D0/en unknown
- 1995-02-03 FI FI950485A patent/FI950485A/en not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
WO1989006233A1 (en) * | 1988-01-07 | 1989-07-13 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
WO1991000277A1 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Substituted imidazoles |
WO1991000281A2 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Fused-ring aryl substituted imidazoles |
EP0434249A2 (en) * | 1989-12-01 | 1991-06-26 | Glaxo Group Limited | Benzofuran derivatives |
EP0459136A1 (en) * | 1990-04-27 | 1991-12-04 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
WO1992000977A2 (en) * | 1990-07-13 | 1992-01-23 | E.I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives |
US5137902A (en) * | 1990-07-13 | 1992-08-11 | E. I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives and anti-hypertensive use thereof |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
US5646171A (en) * | 1991-02-21 | 1997-07-08 | Sankyo Company, Limited | Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use |
US5459148A (en) * | 1992-12-17 | 1995-10-17 | Sankyo Company, Limited | Biphenyl derivatives and their use for the treatment of hypertension and cardiac disease |
US5925664A (en) * | 1994-03-16 | 1999-07-20 | Sankyo Company, Limited | Method for treating ocular hypertension and glaucoma |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
US6271375B1 (en) | 1997-06-30 | 2001-08-07 | Zambon Group S.P.A. | Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes |
US6573288B1 (en) * | 1998-05-06 | 2003-06-03 | Aventis Pharma Deutschland Gmbh | Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
US6369236B1 (en) * | 1998-07-18 | 2002-04-09 | Aventis Pharma Deutschland Gmbh | Imidazole derivatives with biphenylsulfonyl substitution method for preparing them and their use as a drug or diagnostic agent |
US6372917B1 (en) * | 1998-07-18 | 2002-04-16 | Aventis Pharma Deutschland Gmbh | Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them |
US20060135780A1 (en) * | 2003-01-16 | 2006-06-22 | Gennady Nisnevich | Novel synthesis of irbesartan |
US7217825B2 (en) | 2003-01-16 | 2007-05-15 | Teva Pharmaceutical Industries Ltd. | Synthesis of irbesartan |
WO2004065383A3 (en) * | 2003-01-16 | 2004-12-16 | Teva Pharma | Novel synthesis of irbesartan |
EP2189457A1 (en) * | 2003-01-16 | 2010-05-26 | Teva Pharmaceutical Industries Ltd. | Novel synthesis of irbesartan |
US7019148B2 (en) | 2003-01-16 | 2006-03-28 | Teva Pharmaceutical Industries, Ltd. | Synthesis of irbesartan |
US7301035B2 (en) | 2003-01-16 | 2007-11-27 | Teva Pharmaceutical Industries Ltd. | Intermediates for the synthesis of irbesartan |
WO2004065383A2 (en) * | 2003-01-16 | 2004-08-05 | Teva Pharmaceutical Industries Ltd. | Novel synthesis of irbesartan |
US20060135544A1 (en) * | 2003-01-16 | 2006-06-22 | Gennady Nisnevich | Novel synthesis of irbesartan |
US7838683B2 (en) | 2003-01-16 | 2010-11-23 | Teva Pharmaceutical Industries Ltd. | Synthesis of irbesartan |
US20070213539A1 (en) * | 2003-01-16 | 2007-09-13 | Gennady Nisnevich | Novel synthesis of irbesartan |
US7227026B2 (en) | 2003-01-16 | 2007-06-05 | Teva Pharmaceutical Industries Ltd. | Synthesis of irbesartan |
US20040192713A1 (en) * | 2003-01-16 | 2004-09-30 | Gennady Nisnevich | Novel synthesis of irbesartan |
US7875637B2 (en) | 2004-02-25 | 2011-01-25 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use as a II receptor antagonist |
US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
US20060281795A1 (en) * | 2004-02-25 | 2006-12-14 | Takanobu Kuroita | Benzinidazole Derivative and Use As AII Receptor Antagonist |
US20090270464A1 (en) * | 2004-02-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use as a II receptor antagonist |
US20050187269A1 (en) * | 2004-02-25 | 2005-08-25 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
US7572920B2 (en) | 2004-02-25 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use as a II receptor antagonist |
US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20100076200A1 (en) * | 2004-09-02 | 2010-03-25 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20060074117A1 (en) * | 2004-09-02 | 2006-04-06 | Lilach Hedvati | Purification of olmesartan medoxomil |
US20090123538A1 (en) * | 2005-04-20 | 2009-05-14 | Alani Laman L | Angiotensin II Receptor Antagonists |
WO2006115834A1 (en) * | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
IL106553A0 (en) | 1993-12-08 |
MX9304787A (en) | 1995-01-31 |
AU688735B2 (en) | 1998-03-19 |
BR9306911A (en) | 1998-12-08 |
JPH08500103A (en) | 1996-01-09 |
SG47108A1 (en) | 1998-03-20 |
ZA935693B (en) | 1995-02-06 |
CA2141692A1 (en) | 1994-02-17 |
NO950404D0 (en) | 1995-02-03 |
EP0654027A1 (en) | 1995-05-24 |
WO1994003435A1 (en) | 1994-02-17 |
CA2141692C (en) | 2006-05-30 |
JP2892838B2 (en) | 1999-05-17 |
SK13195A3 (en) | 1995-07-11 |
FI950485A0 (en) | 1995-02-03 |
CN1090275A (en) | 1994-08-03 |
PL307309A1 (en) | 1995-05-15 |
HU9500349D0 (en) | 1995-03-28 |
TW239131B (en) | 1995-01-21 |
AU4790393A (en) | 1994-03-03 |
FI950485A (en) | 1995-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5310929A (en) | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists | |
FI114983B (en) | New angiotensin II antagonising benzimidazole derivs. - used for treating hypertension, circulatory diseases, e.g. heart failure, strokes, cerebral apoplexy, nephropathy and nephritis | |
US5512681A (en) | Angiotensin II receptor blocking imidazolinone derivatives | |
US5424450A (en) | Angiotensin II receptor blocking imidazolinone derivatives | |
JP3290657B2 (en) | Acidic aralkyltriazole derivatives active as angiotensin II antagonists | |
US5962491A (en) | Benzimidazole derivatives and use thereof | |
US4880804A (en) | Angiotensin II receptor blocking benzimidazoles | |
US5312820A (en) | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines | |
US5883111A (en) | Heterocyclic compounds and their use as angiotensin antagonists | |
SK279004B6 (en) | 2,6-substituted 3-££2'-(1h-tetrazol-5-yl)£1,1'-bipehnyl|-4- -yl|methyl-4(3h)-quinazoline compound, method and intermediate products for its preparation and pharmaceutical composition on its base | |
IE82833B1 (en) | Pharmaceutical compositions comprising angiotensin ii receptor blocking imidazoles and diuretics | |
JPH06505715A (en) | Compound | |
US6232334B1 (en) | Benzimidazole derivatives, their production and use | |
US5500427A (en) | Cyclic compounds and their use | |
EP0526001A1 (en) | Substituted triazolinones | |
JPS63316778A (en) | 3-heteroalkyl-2,4-quinazolinedione, 3-heteroaryl- 1,2,3-benzotriazine-4(3h)-one, 3-heteroarylalkyl- 4-quinazolinone | |
RU2168510C2 (en) | Heterocyclic compound, pharmaceutical composition, method of antagonism of angiotensin-ii | |
RU2144022C1 (en) | N-(biphenylmethyl)aminobenzoic acid esters and method of their synthesis | |
RU2052455C1 (en) | Benzimidazole derivatives, pharmaceutically acceptable salts thereof, stable crystal and composition for inhibiting angiotensine ii | |
JPH04330072A (en) | Pyrimidinedione derivative | |
KR20100110438A (en) | The novel ester of olmesartan, intermediates thereof, preparation thereof and pharmaceutical composition comprising the same | |
CZ20002757A3 (en) | 2,3,4,5-tetrahydro-1H/1,4/-benzodiazepin-3-hydroxamic acids | |
HUT69701A (en) | 3-(quinolin-6-yl-methyl)-4h-imidazol-4-one derivatives and their preparation | |
JPH0625231A (en) | Isonidazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: E.I. DU PONT DE NEMOURS AND COMPANY, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARDECKY, ROBERT J.;ENSINGER, CAROL L.;PRUITT, JAMES R.;REEL/FRAME:006605/0993 Effective date: 19920806 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: E.I. DU PONT DE NEMOURS AND COMPANY, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUPONT PHARMACEUTICALS COMPANY;REEL/FRAME:012987/0968 Effective date: 20011001 |
|
AS | Assignment |
Owner name: E. I. DU PONT DE NEMOURS AND COMPANY, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUPONT PHARMACEUTICALS COMPANY;REEL/FRAME:015886/0916 Effective date: 20011001 |
|
AS | Assignment |
Owner name: E. I. DU PONT DE NEMOURS AND COMPANY, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUPONT PHARMACEUTICALS COMPANY;REEL/FRAME:015896/0482 Effective date: 20011001 |
|
FPAY | Fee payment |
Year of fee payment: 12 |